On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading company focused on treatment of rare diseases. 

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company with an international market presence. The company is focused on providing and developing orphan and niche specialist pharmaceuticals to patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line within rare diseases. Swedish Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: BVT) is listed on NASDAQ OMX Stockholm.

Our Communication department supports Biovitrum’s business operations with clear, rapid and relevant information about our company, our research and development, and our services. It is our ambition to provide all of our stakeholders with high-quality information, thereby facilitating a thorough knowledge of and an active interest in our company and its operations.

Would you like to order a printed copy of the Annual Report?